Cargando…

Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review

BACKGROUND: Asthma is a highly prevalent chronic inflammatory airways disease, with a considerable impact on quality of life (QoL). To express the effects of asthma on patients’ subjective experience, patient-reported outcomes (PROs) represent an important instrument. The asthma QoL questionnaire (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colombo, Giorgio Lorenzo, Di Matteo, Sergio, Martinotti, Chiara, Oselin, Martina, Valentino, Maria Chiara, Bruno, Giacomo Matteo, Pitotti, Claudia, Menzella, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492364/ https://www.ncbi.nlm.nih.gov/pubmed/31035904 http://dx.doi.org/10.1177/1753466619841350

Ejemplares similares

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study
por: Canonica, Giorgio Walter, et al.
Publicado: (2020)

Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes
por: Torre, Enrico, et al.
Publicado: (2018)

The preventive effect on respiratory tract infections of Oscillococcinum(®). A cost-effectiveness analysis
por: Colombo, Giorgio L, et al.
Publicado: (2018)

Long-term benefits of omalizumab in a patient with severe non-allergic asthma
por: Menzella, Francesco, et al.
Publicado: (2011)

Immunological Aspects Related to Viral Infections in Severe Asthma and the Role of Omalizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II
por: Torre, Enrico, et al.
Publicado: (2020)

Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL
por: Menzella, Francesco, et al.
Publicado: (2023)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives
por: Torre, Enrico, et al.
Publicado: (2022)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma
por: Zafari, Zafar, et al.
Publicado: (2016)

Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis
por: Chong, Weikun, et al.
Publicado: (2023)

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
por: Menzella, Francesco, et al.
Publicado: (2017)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
por: Torre, Enrico, et al.
Publicado: (2020)

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative
por: Colombo, Giorgio L, et al.
Publicado: (2018)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
por: Canonica, Giorgio Walter, et al.
Publicado: (2019)

Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
por: Bergantini, Laura, et al.
Publicado: (2021)

Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life
por: Menzella, Francesco, et al.
Publicado: (2022)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Economic Impact of COVID-19 Lockdown on Italian NHS: Focus on Diabetes Mellitus
por: Torre, Enrico, et al.
Publicado: (2021)

Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap
por: Ricciardi, Luisa, et al.
Publicado: (2022)

The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study
por: Bhutani, Mohit, et al.
Publicado: (2017)

Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma
por: Hanania, Nicola A., et al.
Publicado: (2022)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
por: Zafari, Zafar, et al.
Publicado: (2018)

Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
por: Nishima, Sankei, et al.
Publicado: (2019)

Omalizumab for the treatment of severe allergic asthma in children: A tale of two
por: Brannick, Sinéad, et al.
Publicado: (2022)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
por: Torres-Duque, Carlos A., et al.
Publicado: (2022)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
por: Tajiri, Tomoko, et al.
Publicado: (2023)

Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
por: Curtiss, Frederic R.
Publicado: (2005)

Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study
por: Su, Nan, et al.
Publicado: (2023)

Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study
por: Wang, Wen, et al.
Publicado: (2023)

Omalizumab treatment of moderate to severe asthma in the adolescent and pediatric population
por: O’Quinn, John, et al.
Publicado: (2014)

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
por: Canonica, Giorgio Walter, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6ncp8jkrb0ovlm6vh1ul6ocnmm